Metabolopathies
Between 1-2 cases per 1,000 newborns suffer from metabolic disorders that, in the absence of adequate treatment, can lead to serious and irreversible problems.
Home / Exomas dirigidos / Metabolopatías
Clinical areas
Documentation
Metabolic diseases I 2 studies
Inborn errors of the metabolism are a group of rare diseases caused by genetic defects that involve failure of the metabolic pathways. An increasing number of these syndromes can be treated if they are diagnosed at an early stage. We provide the study of 76 genes associated with the diseases included in the neonatal screening program recommended by the AEP, AAP and ACMG.
DG Neonatal Metabolism (76 genes)
DG Extended Metabolism (257 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Amino Acid Metabolism I 19 studies
Congenital defects of amino acid metabolism are caused by disorders in both the synthesis and degradation of amino acids. Their early detection is essential to avoid serious and irreversible consequences. Through the different studies we approach the diagnosis of the main alterations in the metabolism of amino acids such as phenylketonuria, acidurias or alterations in the urea cycle.
Acidurias
DG Acidurias (49 genes)
Canavan disease (1 gene)
3-methylglutaconic acidurias (8 genes)
Glutaric Acidemia Type I (1 gene)
Isovaleric Acidemia (1 gen)
Isolated methylmalonic acidemia (5 genes)
Mevalonic Aciduria (1 gene)
Propionic aciduria (2 genes)
Urea cycle disorders
Hypophosphatasia (7 genes)
Hyperammonemia (18 genes)
Urea cycle alterations (9 genes)
Amino acid metabolism
DG Aa metabolism (34 genes)
Maple syrup urine disease (5 genes)
Classical homocystinuria (1 gene)
Cystinosis (1 gene)
Tyrosinemia (types I, II and III) (3 genes)
Non-phenylalaninemia, non-phenylketonuric hyperphenylalaninemia (4 genes)
Phenylketonuria (1 gene)
Cystinuria (2 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Carbohydrate metabolism I 5 studies
Carbohydrate metabolism refers to the biochemical processes of formation, breakdown and conversion of carbohydrates in the body. Through the different panels we approach the study of the main diseases associated with defects in carbohydrate metabolism such as glycogen storage disease, fructose metabolism disorders and galactosemia.
Glycogen storage disease
Glycogen storage disease (Glycogenosis) (26 genes)
Glycogen storage disease type 1a (1 gene)
Glycogenosis Type II (Pompe disease) (1 gene)
Fructose metabolism disorder
Fructose Metabolism Disorder (3 genes)
Galactosemia
Galactosemia (5 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Disorder of glycosylation I 1 study
This group of diseases is characterized by defects of enzymes involved in glycosylation processes. Glycosylation consists of the modification of proteins and other macromolecules by the addition of a carbohydrate. Our panel includes the study of genes with a proven association to this type of pathology.
DG Congenital Glycosylation Disorder (106 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Disorder of lipid metabolism I 1 study
This group of diseases is caused by a deficit or malfunction of the enzymes responsible for lipid degradation, resulting in the accumulation of lipids in the body. We perform the diagnosis of this type of disorders by means of a targeted exome that includes the study of the associated genes.
DG Disorder of lipid metabolism (67 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Energy metabolism I 2 studies
Energy metabolism refers to the set of metabolic pathways that aim to generate energy to meet the energy needs of the organism. Through the different panels we approach the study of the genes involved in fatty acid oxidation and ketogenesis and disorders of pyruvate metabolism.
DG Fatty acid oxidation and ketogenesis (13 genes)
Disorders of pyruvate metabolism (7 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Lysosomal disease I 12 studies
They are caused by the inability to degrade macromolecules due to a specific functional defect. Due to this dysfunction, macromolecules accumulate in the lysosome leading to various diseases. Through the different panels we approach the study of the main lysosomal diseases such as mucopolysaccharidosis or Tay-Sachs disease among others.
DG Lysosomal disease (57 genes)
Krabbe disease (2 genes)
Niemann-Pick disease (3 genes)
Mucolipidosis (3 genes)
Fabry disease (1 gene)
Gaucher disease (2 genes)
Ceroid Neuronal Lipofuscinosis (12 genes)
Mucopolysaccharidosis
DG Mucopolysaccharidosis (MPS) (17 genes)
Mucopolysaccharidosis Type I (1 gene)
Mucopolysaccharidosis Type II (1 gene)
Sanfilippo disease (MPS III) (4 genes)
Morquio disease (MPSIV) (2 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Disorders of absorption and transport of metabolites I 7 studies
They refer to a group of diseases characterized by defects in the absorption and transport of any molecule involved in the cellular metabolism. Through the different panels we approach the study of diseases caused by metal metabolism disorders and defects related to the transport of vitamins.
DG Vitamin-related defects (10 genes)
Disorder of metal metabolism
DG Metal Metabolism (21 genes)
Copper Metabolism Disorder (2 genes)
Menkes disease (1 gene)
Wilson's disease (1 gene)
Iron Metabolism Disorder (19 genes)
Neurodegenerative diseases with brain iron accumulation (ENACH) (6 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Peroxisomal disease I 4 studies
Peroxisomes are cellular organelles responsible for transforming some compounds into others by means of enzymes inside them. Among their main functions are to carry out the oxidative reactions of degradation of fatty acids and amino acids. The dysfunction of these enzymes gives rise to different diseases such as Zellweger's Syndrome or Adrenoleukodystrophy, pathologies for which we have specific panels.
DG Peroxisomal disease (34 genes)
Zellweger syndrome (13 genes)
X-linked cerebral adrenoleukodystrophy (1 gene)
Peroxisomal acyl CoA oxidase deficiency (1 gene) gene)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Defects in the metabolism of purines and pyriminides I 2 studies
Defects in purine and pyrimidine metabolism affect nucleotide metabolism. Deficiencies in the enzymes involved in their synthesis or degradation lead to the development of diseases. Through the different panels we approach the study of the main genes involved in the metabolism of these components.
DG Purine and pyrimidine defects (5 genes)
Lesch-Nyhan syndrome (1 gene)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days
Defects in the metabolism of neurotransmitters and neuromodulators I 1 study
Neurotransmitters are chemical substances that release, amplify and modulate signals between neurons to communicate with each other and neuromodulators are substances secreted at a synapse that influence the postsynaptic consequences of neurotransmission. Defects in the metabolism of these substances lead to the development of disease. We approach their diagnosis by studying the main genes involved in the processes of neurotransmission and neuromodulation.
DG Neurotransmitter and neuromodulator defects (5 genes)
Information
-
Analysis: SNVs, Indels and CNVs -
Medium coverage: >100X -
Delivery time: 30 working days